SCTC21C / Sinocelltech - LARVOL DELTA

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Sinocelltech Ltd.

New P3 trial • Amyloidosis

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov) - P3 | N=292 | Recruiting | Sponsor: Sinocelltech Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov) - P3 | N=292 | Not yet recruiting | Sponsor: Sinocelltech Ltd.

New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases (clinicaltrials.gov) - P1/2 | N=99 | Not yet recruiting | Sponsor: Sinocelltech Ltd.

New P1/2 trial • Glomerulonephritis • IgA Nephropathy • Immunology • Renal Disease

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: Sinocelltech Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=74 | Not yet recruiting | Sponsor: Sinocelltech Ltd.

New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology